Welcome to our dedicated page for LEMAITRE VASCULAR SEC filings (Ticker: LMAT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on LEMAITRE VASCULAR's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into LEMAITRE VASCULAR's regulatory disclosures and financial reporting.
LeMaitre Vascular (LMAT) filed a Form 144 reporting a proposed sale of 10,815 common shares on NASDAQ with an aggregate market value of $999,173.07. The form states these shares equal roughly 0.048% of the 22,637,522 shares outstanding. The securities were acquired and are being sold on 08/11/2025 through a stock option exercise, with payment in cash, and the sale is to be executed through Morgan Stanley Smith Barney LLC. The filing notes no securities sold in the past three months by the selling person and includes the filer’s representation that they are unaware of any undisclosed material adverse information.
LeMaitre Vascular insider sale summary: George W. LeMaitre, who serves as Chairman and CEO and is a company director, reported a sale of 100,000 shares of LeMaitre Vascular Inc. (LMAT) on 08/06/2025. The sale was executed under a pre-established 10b5-1(c) trading plan adopted on 03/10/2025 and was carried out in multiple trades at a weighted average price of $93.5053, with individual trades ranging from $93.03 to $94.00. After the reported transaction, the reporting person beneficially owned 1,727,003 shares. The filer notes willingness to provide full trade-level details on request. No derivative transactions were reported on this Form 4.
LeMaitre Vascular (LMAT) submitted a Form 144 reporting a proposed sale of 939 shares of common stock with an aggregate market value of $87,784.39. The notice names Morgan Stanley Smith Barney LLC as broker and lists the approximate sale date as 08/08/2025 on NASDAQ, and shows 22,637,522 shares outstanding.
The filing states the securities were acquired on 08/08/2025 by a stock option exercise from the issuer and paid in cash. The section for securities sold in the past three months is marked "Nothing to Report". The form includes the standard attestation that the seller does not possess undisclosed material adverse information and references Rule 144 disclosure requirements.
LeMaitre Vascular, Inc. Form 144 reports a proposed sale of 2,500 common shares on NASDAQ through Morgan Stanley Smith Barney LLC with an aggregate market value of $235,000 and an approximate sale date of 08/08/2025. The filing lists 22,637,522 shares outstanding, showing the reported sale is a very small fraction of the companys outstanding stock.
The securities-to-be-sold were recorded as acquired by a stock option exercise on 08/08/2025 with payment in cash. The filing also discloses a prior sale by Bridget A Ross of 3,750 shares on 05/12/2025 for $312,000. Several filer identification fields (for example Filer CIK and Filer CCC) are not populated in the provided text. The signer affirms no undisclosed material adverse information.
On Form 144, insider George W. LeMaitre filed notice to sell 100,000 common shares of LeMaitre Vascular Inc. (LMAT) through Charles Schwab on or about 6 Aug 2025. At the referenced price, the block is valued at $9.35 million and represents roughly 0.44 % of the 22.64 million shares outstanding.
The filing also lists three prior sales by the same holder between 16–20 May 2025 totaling 100,000 shares for $10.71 million in gross proceeds. The shares being disposed of were originally acquired on 2 Jun 1997 via a promissory-note transaction.
No operational or financial results are provided; the document strictly satisfies Rule 144 disclosure requirements. Nevertheless, the continued insider dispositions may create a modest share-supply overhang and could be interpreted as a signal of profit-taking ahead of the August execution date.